A New Hope for IgA Nephropathy Patients Recent clinical developments have brought a glimmer of hope to those suffering from IgA nephropathy (IgAN), a chronic autoimmune kidney disease. Genentech, a member of the Roche Group, recently announced positive interim data from their clinical trial of sefaxersen, an investigational therapy designed to tackle the underlying causes…